• Recruiting

NCT04499339: Phase 1/2: Autologous SLAMF7 CAR-T Cells in Multiple Myeloma - RRMM - CARAMBA-1

CARAMBA-1 - NCT04499339: Phase 1/2: Autologous SLAMF7 CAR-T Cells in Multiple Myeloma

CARAMBA-1 - NCT04499339: Phase 1/2:  Autologous SLAMF7 CAR-T Cells in Multiple Myeloma

CARAMBA-1 - NCT04499339: Phase 1/2: Autologous SLAMF7 CAR-T Cells in Multiple Myeloma


A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma


CARAMBA-1 is a first-in-human clinical trial of adoptive immunotherapy with autologous signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR)-T cells in patients with advanced MM that have exhausted conventional therapies.


The CARAMBA-1 clinical trial is an open-label, non-randomized, multicenter clinical trial which combines a phase I dose-escalation part with a phase IIa dose-expansion part to assess feasibility, safety and anti-myeloma activity of SLAMF7 CAR-T cells. The CARAMBA project and the CARAMBA-1 clinical trial are supported by the European Union in the Horizon 2020 research and innovation program.


Sponsor

Wuerzburg University Hospital


Collaborator

European Union

 

ClinicalTrials.gov Identifier: NCT04499339

Official Title: A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma

First Posted : August 5, 2020

Click here to see details on ClinicalTrials.gov

 

Drug: SLAMF7 CAR-T

Single infusion of autologous SLAMF7 CAR-T cells

 

Locations

Europe

Germany

Spain


Posts Archive